Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
Tweet Send to a Friend
BMO Capital analyst, Ian Somaiya, cut his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160 from $168 following disappointing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
